→ The market overall may be in turmoil, but why should that bother the record-setting biotech IPO from Arie Belldegrun and David Chang. Allogene stock $ALLO charged up on its debut Thursday and was still rising on Friday, shooting past the $27 mark after starting off at $18 a share. Allogene raised a record $324 million on its pricing, a figure that will likely grow as the underwriters pick up their options. The biotech is focused on winning the race to the first off-the-shelf CAR-T, with two big clinical programs slated to begin next year.
→ We’ve been hearing a lot about bigger and bigger IPOs this year. Now we’re also seeing the mini-me version come along. Hoth Therapeutics out of New York just filed for a $13 million IPO to back their work on a new therapy to prevent eczema. Hoth in-licensed rights to a tech that combines an “FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.Free Subscription